natgillin/translations-raw huggingface dataset:
3 years for contracts entered into or novated before 9 October 2016 that belong to the classes in Table 2 set out in Annex I;
3 leta za pogodbe, sklenjene ali prenovljene pred 9. oktobrom 2016, ki spadajo v razrede v tabeli 2 iz Priloge I;
6 months for contracts entered into or novated on or after 9 October 2016 that belong to the classes in Table 1 or Table 2 set out in Annex I.
6 mesecev za pogodbe, sklenjene ali prenovljene 9. oktobra 2016 ali po njem, ki spadajo v razrede v tabeli 1 ali tabeli 2 iz Priloge I.
3 years for contracts entered into or novated 9 October 2016 that belong to the classes in Table 2 set out in Annex I;
3 leta za pogodbe, sklenjene ali prenovljene pred 9. oktobrom 2016, ki spadajo v razrede v tabeli 2 iz Priloge I;
15 years for contracts that belong to the classes in Table 1 set out in Annex I;
15 let za pogodbe, ki spadajo v razrede v tabeli 1 iz Priloge I;
3 years for contracts that belong to the classes in Table 2 set out in Annex I.
3 leta za pogodbe, ki spadajo v razrede v tabeli 2 iz Priloge I.
Where a contract is concluded between two financial counterparties belonging to different categories or between two financial counterparties involved in transactions referred to in Article 3(2), the minimum remaining maturity to be taken into account for the purposes of this Article shall be the longer remaining maturity applicable.
Če se pogodba sklene med dvema finančnima nasprotnima strankama, ki spadata v različni kategoriji, ali med dvema finančnima nasprotnima strankama, vključenima v transakcije iz člena 3(2), je minimalna preostala zapadlost, ki jo je treba upoštevati za namene tega člena, najdaljša od preostalih zapadlosti, ki se uporabljajo.
Done at Brussels, 10 June 2016.
V Bruslju, 10. junija 2016
Regulation (EU) No 1095/2010 of the European Parliament and the Council of 24 November 2010 establishing a European Supervisory Authority (European Securities and Markets Authority), amending Decision No 716/2009/EC and repealing Commission Decision 2009/77/EC (OJ L 331, 15.12.2010, p. 84).
Uredba (EU) št. 1095/2010 Evropskega parlamenta in Sveta z dne 24. novembra 2010 o ustanovitvi Evropskega nadzornega organa (Evropski organ za vrednostne papirje in trge) in o spremembi Sklepa št. 716/2009/ES ter razveljavitvi Sklepa Komisije 2009/77/ES (UL L 331, 15.12.2010, str. 84).
Commission Delegated Regulation (EU) 2015/2205 of 6 August 2015 supplementing Regulation (EU) No 648/2012 of the European Parliament and of the Council with regard to regulatory technical standards on the clearing obligation (OJ L 314, 1.12.2015, p.
Delegirana uredba Komisije (EU) 2015/2205 z dne 6. avgusta 2015 o dopolnitvi Uredbe (EU) št. 648/2012 Evropskega parlamenta in Sveta v zvezi z regulativnimi tehničnimi standardi za obveznost kliringa (UL L 314, 1.12.2015, str.
Directive 2011/61/EU of the European Parliament and of the Council of 8 June 2011 on Alternative Investment Fund Managers and amending Directives 2003/41/EC and 2009/65/EC and Regulations (EC) No 1060/2009 and (EU) No 1095/2010 (OJ L 174, 1.7.2011, p.
Direktiva 2011/61/EU Evropskega parlamenta in Sveta z dne 8. junija 2011 o upraviteljih alternativnih investicijskih skladov in spremembah direktiv 2003/41/ES in 2009/65/ES ter uredb (ES) št. 1060/2009 in (EU) št. 1095/2010 (UL L 174, 1.7.2011, str.
Directive 2009/65/EC of the European Parliament and of the Council of 13 July 2009 on the coordination of laws, regulations and administrative provisions relating to undertakings for collective investment in transferable securities (UCITS) (OJ L 302, 17.11.2009, p. 32).
Direktiva 2009/65/ES Evropskega parlamenta in Sveta z dne 13. julija 2009 o usklajevanju zakonov in drugih predpisov o kolektivnih naložbenih podjemih za vlaganja v prenosljive vrednostne papirje (KNPVP) (UL L 302, 17.11.2009, str.
Interest rate OTC derivatives classes subject to the clearing obligation
PRILOGA
Table 1
Razredi obrestnih izvedenih finančnih instrumentov OTC, za katere velja obveznost kliringa
Fixed-to-float interest rate swaps classes
Tabela 1
Type
Razredi zamenjav fiksne za variabilno obrestno mero
Reference Index
Vrsta
Settlement Currency
Referenčni indeks
Maturity
Valuta poravnave
Settlement Currency Type
Zapadlost
Notional Type
Izbirnost (optionality)
Fixed-to-float
Vrsta nominalnega zneska
Single currency
ena valuta
Constant or variable
konstantna ali variabilna
Having regard to Regulation (EC) No 1272/2008 of the European Parliament and of the Council of 16 December 2008 on classification, labelling and packaging of substances and mixtures, amending and repealing Directives 67/548/EEC and 1999/45/EC, and amending Regulation (EC) No 1907/2006 [1], and in particular Article 37(5) thereof,
ob upoštevanju Uredbe (ES) št. 1272/2008 Evropskega parlamenta in Sveta z dne 16. decembra 2008 o razvrščanju, označevanju in pakiranju snovi ter zmesi, o spremembi in razveljavitvi direktiv 67/548/EGS in 1999/45/ES ter spremembi Uredbe (ES) št. 1907/2006 [1], zlasti člena 37(5) Uredbe,
Since Directive 67/548/EEC has been repealed with effect from 1 June 2015, Table 3.2 in Part 3 of Annex VI should be deleted.
Ker je bila Direktiva 67/548/EGS razveljavljena z učinkom od 1. junija 2015 bi bilo treba tabelo 3.2 v delu 3 Priloge VI črtati.
However, in order to ease the transition to full applicability of Regulation (EC) No 1272/2008, that deletion should not take effect until 1 June 2017.
Da bi olajšali prehod k polni uporabi Uredbe (ES) št. 1272/2008, navedeno črtanje ne bi smelo začeti veljati do 1. junija 2017.
Proposals for new, updated or deleted harmonised classification and labelling of certain substances have been submitted to the European Chemicals Agency (ECHA) pursuant to Article 37 of Regulation (EC) No 1272/2008.
Predlogi za nove, posodobljene ali črtane usklajene razvrstitve in označitve nekaterih snovi so bili v skladu s členom 37 Uredbe (ES) št. 1272/2008 poslani Evropski agenciji za kemikalije (ECHA).
Based on the opinions on those proposals issued by the Committee for Risk Assessment of ECHA (RAC), as well as on the comments received from the parties concerned, it is appropriate to introduce, update or delete harmonised classification and labelling of certain substances.
Na podlagi mnenj o navedenih predlogih, ki jih je izdal Odbor za oceno tveganja (RAC) pri Evropski agenciji za kemikalije (ECHA), ter na podlagi pripomb zainteresiranih strani je primerno uvesti, posodobiti ali črtati usklajeno razvrščanje in označevanje nekaterih snovi.
With regard to the substance lead, RAC proposes in its scientific opinion of 5 December 2013 to classify it as toxic for reproduction category 1A.
RAC v svojem znanstvenem mnenju z dne 5. decembra 2013 predlaga, da se svinec razvrsti kot strupen za razmnoževanje iz kategorije 1A.
However, in view of the lack of certainty regarding the bioavailability of lead in the massive form, a distinction needs to be made between the massive form (particle size more than or equal to 1 mm) and the powder form (particle size of less than 1 mm).
Vendar pa je zaradi pomanjkanja gotovosti glede biološke dostopnosti svinca v masivni obliki treba razlikovati med masivno obliko (velikost delcev 1 mm ali več) in prahom (velikost delcev do 1 mm).
It is therefore appropriate to introduce a specific concentration limit (SCL) of ≥ 0,03 % for the powder form and a generic concentration limit (GCL) of ≥ 0,3 % for the massive form.
Zato je primerno uvesti posebno mejno koncentracijo (SCL) ≥ 0,03 % za prah in splošno mejno koncentracijo (GCL) ≥ 0,3 % za masivno obliko.
With regard to the copper substances, the environmental classification recommended in the RAC opinions of 4 December 2014 should be included in Annex VI to Regulation (EC) No 1272/2008 since sufficient scientific evidence is available justifying this new classification.
RAC je v svojih mnenjih z dne 4. decembra 2014 glede snovi, ki vsebujejo baker, priporočil, da je treba v Prilogo VI k Uredbi št. 1272/2008 vključiti razvrščanje z vidika nevarnosti za okolje, saj je na voljo dovolj znanstvenih dokazov, ki to novo razvrščanje upravičujejo.
However, the proposed M-factors for long-term aquatic hazard should not be included since they require further assessment by RAC in view of scientific data on aquatic toxicity presented by industry after the RAC opinion was forwarded to the Commission.
Vključiti pa ne bi smeli predlaganih M-faktorjev za dolgotrajno nevarnost za vodno okolje, saj jih mora RAC dodatno oceniti glede na znanstvene podatke o strupenosti za vodno okolje, ki jih je industrija predstavila po tem, ko je RAC predložil svoje mnenje Komisiji.
Regulation (EC) No 1272/2008 should be amended accordingly.
Zato bi bilo treba Uredbo (ES) št. 1272/2008 ustrezno spremeniti.
Compliance with the new harmonised classifications should not be required immediately, as a certain period of time will be necessary to allow suppliers to adapt the labelling and packaging of substances and mixtures to the new classifications and to sell existing stocks.
Skladnost z novimi usklajenimi razvrstitvami se ne bi smela zahtevati takoj, ker bodo dobavitelji potrebovali določeno obdobje za prilagoditev označevanja in pakiranja snovi in zmesi novim razvrstitvam ter prodajo obstoječih zalog.
This period of time will also be necessary to allow suppliers to adapt to and to comply with other legislative obligations resulting from the new harmonised classifications for substances such as those provided for in Article 22(f) or Article 23 of Regulation (EC) No 1907/2006 of the European Parliament and of the Council [3], those provided for in Article 50 of Regulation (EU) No 528/2012 of the European Parliament and of the Council [4] or those in Article 44 of Regulation (EC) No 1107/2009 of the European Parliament and of the Council [5].
To obdobje bodo dobavitelji potrebovali tudi za prilagoditev in uskladitev z drugimi zakonodajnimi obveznostmi, ki izhajajo iz novih usklajenih razvrstitev za snovi, kot so navedene v členu 22(f) ali členu 23 Uredbe (ES) št. 1907/2006 Evropskega parlamenta in Sveta [3], v členu 50 Uredbe (EU) št. 528/2012 Evropskega parlamenta in Sveta [4] ali členu 44 Uredbe (ES) št. 1107/2009 Evropskega parlamenta in Sveta [5].
Annex VI is amended in accordance with the Annex to this Regulation;
Priloga VI se spremeni v skladu s Prilogo k tej uredbi.
in Annex VI, Table 3.2 is deleted.
V Prilogi VI se črta tabela 3.2.
This Regulation shall apply from 1 March 2018.
Ta uredba se uporablja od 1. marca 2018.
Article 1(2) shall apply from 1 June 2017.
Člen 1(2) se uporablja od 1. junija 2017.
By way of derogation from paragraph 2, substances and mixtures may, before 1 March 2018, be classified, labelled and packaged in accordance with Regulation (EC) No 1272/2008 as amended by this Regulation.
Z odstopanjem od odstavka 2 se lahko snovi in zmesi pred 1. marcem 2018 razvrščajo, označujejo in pakirajo v skladu z Uredbo (ES) št. 1272/2008, kakor je spremenjena s to uredbo.
Council Directive 67/548/EEC of 27 June 1967 on the approximation of laws, regulations and administrative provisions relating to the classification, packaging and labelling of dangerous substances (OJ 196, 16.8.1967, p. 1).
Direktiva Sveta 67/548/EGS z dne 27. junija 1967 o približevanju zakonov in drugih predpisov v zvezi z razvrščanjem, pakiranjem in označevanjem nevarnih snovi (UL 196, 16.8.1967, str. 1).
Regulation (EC) No 1107/2009 of the European Parliament and of the Council of 21 October 2009 concerning the placing of plant protection products on the market and repealing Council Directives 79/117/EEC and 91/414/EEC (OJ L 309, 24.11.2009, p. 1).
Uredba (ES) št. 1107/2009 Evropskega parlamenta in Sveta z dne 21. oktobra 2009 o dajanju fitofarmacevtskih sredstev v promet in razveljavitvi direktiv Sveta 79/117/EGS in 91/414/EGS (UL L 309, 24.11.2009, str. 1);
Table 3.1 of Part 3 of Annex VI to Regulation (EC) No 1272/2008 is amended as follows:
Tabela 3.1 v delu 3 Priloge VI k Uredbi (ES) št. 1272/2008 se spremeni:
the entries corresponding to index numbers 607-331-00-5 and 609-066-00-0 are deleted;
vnosi pri indeksnih številkah 607-331-00-5 in 609-066-00-0 se črtajo;
the entries corresponding to index numbers, 006-035-00-8, 029-002-00-X, 602-020-00-0, 602-033-00-1, 603-055-00-4, 604-030-00-0, 604-092-00-9, 605-013-00-0, 605-022-00-X, 606-014-00-9, 606-021-00-7, 607-056-00-0, 607-059-00-7, 607-157-00-X, 607-172-00-1, 607-375-00-5, 607-623-00-2, 613-166-00-X, 613-121-00-4, 616-011-00-4, 616-037-00-6 and 616-207-00-X are replaced by the following entries respectively:
vnosi pri indeksnih številkah 006-035-00-8, 029-002-00-X, 602-020-00-0, 602-033-00-1, 603-055-00-4, 604-030-00-0, 604-092-00-9, 605-013-00-0, 605-022-00-X, 606-014-00-9, 606-021-00-7, 607-056-00-0, 607-059-00-7, 607-157-00-X, 607-172-00-1, 607-375-00-5, 607-623-00-2, 613-166-00-X, 613-121-00-4, 616-011-00-4, 616-037-00-6 in 616-207-00-X se nadomestijo z naslednjimi vnosi:
EC No
Št.
CAS No
EC
Classification
Št.
Labelling
CAS
Specific Conc.
Razvrstitev
Limits, M-factors
Označitev
Notes
Posebne mejne koncentracije, M-faktorji
Hazard Class and Category Code(s)
Opombe
Hazard statement Code(s)
Razred nevarnosti in oznaka(-e) kategorije
Pictogram, Signal Word Code(s)
Oznaka(-e) stavka o nevarnosti
Suppl.
Piktogram, oznaka(-e) opozorilne besede
Hazard statement Code(s)
Dod. oznaka(-e) stavka o nevarnosti
pirimicarb (ISO); 2-(dimethylamino)-5,6-dimethylpyrimidin-4-yl dimethylcarbamate
pirimikarb (ISO); 2-(dimetilamino)-5,6-dimetilpirimidin-4-il dimetilkarbamat
M = 100’
M = 100“
copper (I) oxide
bakrov(I) oksid
1,2-epoxypropane; methyloxirane
1,2-epoksipropan; metiloksiran
phenol, dodecyl-, branched; [1]
fenol, dodecil-, razvejan; [1]
phenol, 2-dodecyl-, branched; [2]
fenol, 2-dodecil-, razvejan; [2]
phenol, 3-dodecyl-, branched; [3]
fenol, 3-dodecil-, razvejan; [3]
phenol, 4-dodecyl-, branched; [4]
fenol, 4-dodecil-, razvejan; [4]
phenol, (tetrapropenyl) derivatives [5]
fenol (tetrapropenil) derivati [5]
M = 10’
M = 10“
chloralose (INN);
kloralos (INN);
Sens.
klorofacinon (ISO);
‘606-014-00-9
2-[(4-klorofenil)(fenil)acetil]-1H-inden-1,3(2H)-dion
chlorophacinone (ISO);
H372 (kri)
2-[(4-chlorophenyl)(phenyl)acetyl]-1H-indene-1,3(2H)-dione
STOT RE 1; H372 (kri): C ≥ 0,1 %
H372 (blood)
STOT RE 2; H373 (kri):
STOT RE 2; H373 (blood):
N-metil-2-pirolidon; 1-metil-2-pirolidon
‘606-021-00-7
STOT SE 3; H335: C ≥ 10 %“
N-methyl-2-pyrrolidone; 1-methyl-2-pyrrolidone
„607-056-00-0
STOT SE 3; H335: C ≥ 10 %’
varfarin (ISO);
‘607-056-00-0
idroksi-3-(3-okso-1-fenilbutil)-2H-kromen-2-on; [1]
warfarin (ISO);
idroksi-3-(3-okso-1-fenilbutil)-2-benzopiron; [2]
ydroxy-3-(3-oxo-1-phenylbutyl)-2H-chromen-2-one; [1]
idroksi-3-(3-okso-1-fenilbutil)-2-benzopiron [3]
ydroxy-3-(3-oxo-1-phenylbutyl)-2-benzopyrone; [2]
STOT RE 1; H372 (kri): C ≥ 0,5 %
ydroxy-3-(3-oxo-1-phenylbutyl)-2-benzopyrone [3]
STOT RE 2; H373 (kri): 0,05 % ≤ C < 0,5 %“
STOT RE 1; H372 (blood): C ≥ 0,5 %
„607-059-00-7
‘607-059-00-7
STOT RE 1; H372 (kri): C ≥ 1,0 %
coumatetralyl (ISO); 4-hydroxy-3-(1,2,3,4-tetrahydro-1-naphthyl)coumarin
STOT RE 2; H373 (kri) 0,1 % ≤ C < 1,0 %
1B; H360D: C ≥ 0,003 %
„607-157-00-X
STOT RE 1; H372 (blood): C ≥ 1,0 %
difenakum (ISO); 3-(3-bifenil-4-il-1,2,3,4-tetrahidro-1-naftil)-4-hidroksikumarin
STOT RE 2; H373 (blood) 0,1 % ≤ C < 1,0 %
C ≥ 0.003 %
‘607-157-00-X
STOT RE 1; H372 (kri): C ≥ 0,02 % STOT RE 2; H373 (kri):
difenacoum (ISO); 3-(3-biphenyl-4-yl-1,2,3,4-tetrahydro-1-naphthyl)-4-hydroxycoumarin
„607-172-00-1
C ≥ 0,003 %
brodifakum (ISO);
STOT RE 1; H372 (blood): C ≥ 0,02 % STOT RE 2; H373 (blood):
idroksi-3-(3-(4′-bromo-4-bifenilil)-1,2,3,4-tetrahidro-1-naftil)kumarin
‘607-172-00-1
„607-375-00-5
brodifacoum (ISO);
flokumafen (ISO); reakcijska zmes: cis-4-hidroksi-3-(1,2,3,4-tetrahidro-3-(4-(4-trifluorometilbenziloksi)fenil)-1-naftil)kumarina in trans-4-hidroksi-3-(1,2,3,4-tetrahidro-3-(4-(4-trifluorometilbenziloksi)fenil)-1-naftil)kumarina
ydroxy-3-(3-(4′-bromo-4-biphenylyl)-1,2,3,4-tetrahydro-1-naphthyl)coumarin
STOT RE 1; H372 (kri): C ≥ 0,05 %
‘607-375-00-5
„607-623-00-2
flocoumafen (ISO); reaction mass of: cis-4-hydroxy-3-(1,2,3,4-tetrahydro-3-(4-(4-trifluoromethylbenzyloxy)phenyl)-1-naphthyl)coumarin and trans-4-hydroxy-3-(1,2,3,4-tetrahydro-3-(4-(4-trifluoromethylbenzyloxy)phenyl)-1-naphthyl)coumarin
diizobutil ftalat
STOT RE 1; H372 (blood): C ≥ 0,05 %
H360Df“
‘607-623-00-2
„613-166-00-X
diisobutyl phthalate
flumioksazin (ISO);
H360Df’
2-[7-fluoro-3-okso-4-(prop-2-in-1-il)-3,4-dihidro-2H-1,4-benzoksazin-6-il]-4,5,6,7-tetrahidro-1H-izoindol-1,3(2H)-dion
‘613-166-00-X
M = 1000“
flumioxazin (ISO);
„613-121-00-4
2-[7-fluoro-3-oxo-4-(prop-2-yn-1-yl)-3,4-dihydro-2H-1,4-benzoxazin-6-yl]-4,5,6,7-tetrahydro-1H-isoindole-1,3(2H)-dione
klorsulfuron (ISO); 2-kloro-N-[[(4-metoksi-6-metil-1,3,5-triazin-2- il)amino]karbonil]benzensulfonamid
M = 1000’
„616-011-00-4
‘613-121-00-4
N,N-dimetilacetamid
chlorsulfuron (ISO); 2-chloro-N-[[(4-methoxy-6-methyl-1,3,5-triazin-2- yl)amino]carbonyl]benzenesulphonamide
„616-037-00-6
‘616-011-00-4
acetoklor (ISO); 2-kloro-N-(etoksimetil)-N-(2-etil-6-metilfenil)acetamid
N,N-dimethylacetamide
H373 (ledvice)
‘616-037-00-6
„616-207-00-X
acetochlor (ISO); 2-chloro-N-(ethoxymethyl)-N-(2-ethyl-6-methylphenyl)acetamide
poliheksametilen bigvanid hidroklorid;
H373 (kidney)
H372 (respiratorni trakt) (vdihavanje)
‘616-207-00-X
Naslednji vnosi se vstavijo v skladu z zaporedjem indeksnih številk:
polyhexamethylene biguanide hydrochloride;
„005-020-00-3
H372 (respiratory tract) (inhalation)
dinatrijev oktaborat, brezvodni; [1]
the following entries are inserted in accordance with the order of the index numbers:
dinatrijev oktaborat tetrahidrat [2]
‘005-020-00-3
H360FD“
disodium octaborate anhydrous; [1]
„014-046-00-4
disodium octaborate tetrahydrate [2]
mikrovlakna e-stekla reprezentativne sestave; [kalcij-aluminij-silikatna vlakna z naključno usmeritvijo z naslednjo reprezentativno sestavo (z mas. %): SiO2 50,0–56,0 %, Al2O3 13,0–16,0 %, B2O3 5,8–10,0 %, Na2O < 0,6 %, K2O < 0,4 %, CaO 15,0–24,0 %, MgO < 5,5 %, Fe2O3 < 0,5 %, F2 < 1,0 %.
H360FD’
Postopek: običajno proizvedena z zmanjševanjem plamena in z rotacijskim procesom.
‘014-046-00-4
(V majhnih količinah so lahko prisotni dodatni posamezni elementi; postopek ne preprečuje inovacij).]
e-glass microfibres of representative composition; [Calcium-aluminium-silicate fibres with random orientation with the following representative composition (% given by weight): SiO2 50,0-56,0 %, Al2O3 13,0-16,0 %, B2O3 5,8-10,0 %, Na2O < 0,6 %, K2O < 0,4 %, CaO 15,0-24,0 %, MgO < 5,5 %, Fe2O3 < 0,5 %, F2 < 1,0 %.
„014-047-00-X
Process: typically produced by flame attenuation and rotary process.
steklena mikrovlakna reprezentativne sestave; [kalcij-aluminij-silikatna vlakna z naključno usmeritvijo z naslednjo sestavo (z mas. %): SiO2 55,0–60,0 %, Al2O3 4,0–7,0 %, B2O3 8,0–11,0 %, ZrO2 0,0–4,0 %, Na2O 9,5–13,5 %, K2O 0,0–4,0 %, CaO 1,0–5,0 %, MgO 0,0–2,0 %, Fe2O3 < 0,2 %, ZnO 2,0–5,0 %, BaO 3,0–6,0 %, F2 < 1,0 %.
(Additional individual elements may be present at low levels; the process list does not preclude innovation).]
Postopek: običajno proizvedena z zmanjševanjem plamena in z rotacijskim procesom.
‘014-047-00-X
(V majhnih količinah so lahko prisotni dodatni posamezni elementi; postopek ne preprečuje inovacij).]
glass microfibres of representative composition; [Calcium-aluminium-silicate fibres with random orientation with the following composition (% given by weight): SiO2 55,0-60,0 %, Al2O3 4,0-7,0 %, B2O3 8,0-11,0 %, ZrO2 0,0-4,0 %, Na2O 9,5-13,5 %, K2O 0,0-4,0 %, CaO 1,0-5,0 %, MgO 0,0-2,0 %, Fe2O3 < 0,2 %, ZnO 2,0-5,0 %, BaO 3,0-6,0 %, F2 < 1,0 %.
H351 (vdihavanje)
Process: typically produced by flame attenuation and rotary process.
„029-015-00-0
(Additional individual elements may be present at low levels; the process list does not preclude innovation).]
bakrov tiocianat
H351 (inhalation)
„029-016-00-6
‘029-015-00-0
bakrov(II) oksid
copper thiocyanate
„029-017-00-1
‘029-016-00-6
dibakrov klorid trihidroksid
copper(II) oxide
„029-018-00-7
‘029-017-00-1
tetrabakrov heksahidroksid sulfat; [1]
dicopper chloride trihydroxide
tetrabakrov heksahidroksid sulfat hidrat [2]
‘029-018-00-7
„029-019-01-X
tetracopper hexahydroxide sulphate; [1]
bakrove luske (prevlečene s alifatskimi kislinami)
tetracopper hexahydroxide sulphate hydrate [2]
„029-020-00-8
copper flakes (coated with aliphatic acid)
„029-021-00-3
‘029-020-00-8
bakrov dihidroksid;
copper(II) carbonate--copper(II) hydroxide (1:1)
bakrov (II) hidroksid
‘029-021-00-3
„029-022-00-9
copper dihydroxide;
bordojska mešanica;
copper(II) hydroxide
reakcijski produkti bakrovega sulfata s kalcijevim dihidroksidom
Eye Dam.
„029-023-00-4
1
bakrov sulfat pentahidrat
bordeaux mixture;
svinčev prah;
reaction products of copper sulphate with calcium dihydroxide
[premer delcev < 1 mm]
‘029-023-00-4
1A; H360D: C ≥ 0,03 %“
copper sulphate pentahydrate
„082-014-00-7
‘082-013-00-1
masivni svinec:
lead powder;
[premer delcev ≥ 1 mm]
[particle diameter < 1 mm]
„605-040-00-8
Lact.
hidroksiizoheksil 3-cikloheksen karboksaldehid (INCI); reakcijska zmes 4-(4-hidroksi-4-metilpentil)cikloheks-3-en-1-karbaldehida in 3-(4-hidroksi-4-metilpentil)cikloheks-3-en-1-karbaldehida; [1]
1A; H360D: C ≥ 0,03 %’
4-(4-hidroksi-4-metilpentil)cikloheks-3-en-1-karbaldehid; [2]
‘082-014-00-7
3-(4-hidroksi-4-metilpentil)cikloheks-3-en-1-karbaldehid [3]
lead massive:
„607-716-00-8
[particle diameter ≥ 1 mm]
bromadiolon (ISO); 3-[3-(4′-bromobifenil-4-il)-3-hidroksi-1-fenilpropil]-4-hidroksi-2H-kromen-2-on
‘605-040-00-8
STOT RE 1; H372 (kri): C ≥ 0,005 % STOT RE 2; H373 (kri):
hydroxyisohexyl 3-cyclohexene carboxaldehyde (INCI); reaction mass of 4-(4-hydroxy-4-methylpentyl)cyclohex-3-ene-1-carbaldehyde and 3-(4-hydroxy-4-methylpentyl)cyclohex-3-ene-1-carbaldehyde; [1]
0,0005 % ≤ C < 0.005 %
4-(4-hydroxy-4-methylpentyl)cyclohex-3-ene-1-carbaldehyde; [2]
„607-717-00-3
3-(4-hydroxy-4-methylpentyl)cyclohex-3-ene-1-carbaldehyde [3]
difetialon (ISO);
‘607-716-00-8
3-[3-(4′-bromobifenil-4-il)-1,2,3,4-tetrahidronaftalen-1-il]-4-hidroksi-2H-1-benzotiopiran-2-on
bromadiolone (ISO); 3-[3-(4′-bromobiphenyl-4-yl)-3-hydroxy-1-phenylpropyl]-4-hydroxy-2H-chromen-2-one
„607-718-00-9
STOT RE 1; H372 (blood): C ≥ 0,005 % STOT RE 2; H373 (blood):
perfluorononan-1-ojska kislina [1] ter njene natrijeve [2] in amonijeve [3] soli
0,0005 % ≤ C < 0,005 %
H372 (jetra, vranica, priželjc)
‘607-717-00-3
„607-719-00-4
difethialone (ISO);
dicikloheksil ftalat
‘607-718-00-9
3,7-dimetilokta-2,6-diennitril
perfluorononan-1-oic acid [1] and its sodium [2] and ammonium [3] salts
„612-288-00-0
H372 (liver, thymus, spleen)
bupirimat (ISO);
‘607-719-00-4
util-2-etilamino-6-metilpirimidin-4-il dimetilsulfamat
dicyclohexyl phthalate
„612-289-00-6
‘608-067-00-3
triflumizol (ISO);
3,7-dimethylocta-2,6-dienenitrile
(1E)-N-[4-kloro-2-(trifluorometil)fenil]-1-(1H-imidazol-1-il)-2-propoksietanimin
Muta.
H373 (jetra)
‘612-288-00-0
„616-218-00-X
bupirimate (ISO);
benzovindiflupir (ISO); N-[9-(diklorometilen)-1,2,3,4-tetrahidro-1,4-metanonaftalen-5-il]-3-(difluorometil)-1-metil-1H-pirazol-4-karboksamid
utyl-2-ethylamino-6-methylpyrimidin-4-yl dimethylsulphamate
„616-219-00-5
‘612-289-00-6
fluopiram (ISO); N-2-[3-kloro-5-(trifluorometil)piridin-2-il]etil-2-(trifluorometil)benzamid
triflumizole (ISO);
„616-220-00-0
(1E)-N-[4-chloro-2-(trifluoromethyl)phenyl]-1-(1H-imidazol-1-yl)-2-propoxyethanimine
pencikuron (ISO); 1-[(4-klorofenil)metil]-1-ciklopentil-3-fenilsečnina
H373 (liver)
„617-023-00-2
Commission Implementing Regulation (EU) 2016/1180
Izvedbena uredba Komisije (EU) 2016/1180
Commission Implementing Regulation (EU) 2016/1181
Izvedbena uredba Komisije (EU) 2016/1181
fixing the allocation coefficient to be applied to the quantities on which applications for import licences and applications for import rights lodged from 1 to 7 July 2016 are based and establishing the quantities to be added to the quantity fixed for the sub-period from 1 January to 31 March 2017 under the tariff quotas opened by Regulation (EC) No 616/2007 for poultrymeat
o določitvi koeficienta dodelitve, ki se bo uporabil za količine v zahtevkih za uvozna dovoljenja in zahtevkih za uvozne pravice, vloženih od 1. do 7. julija 2016, in določitvi količin, ki se bodo dodale količini, določeni za podobdobje od 1. januarja do 31. marca 2017 v okviru tarifnih kvot, ki so z Uredbo (ES) št. 616/2007 odprte v sektorju za perutnino